Health services

Evidence has emerged that Novartis may have launched a sustained campaign to block the off label use of cancer drug Avastin over its licensed treatment, Lucentis

Clinical commissioning group (CCG) has cancelled plans to switch to Avastin for AMD patients, despite potential NHS savings of more than £100m a year